1 Tufts Medical Center, Boston, Massachusetts (C.E.G.).
2 Hospital Universitari i Politecnic La Fe, Valencia, Spain (M.C.B.).
3 Cairo University, Cairo, Egypt (W.D.).
4 Ospedale Maggiore, Milan, Italy (F.F.).
5 Hôpital Purpan and Centre de Physiopathologie de Toulouse Purpan, Toulouse, France (J.I.).
6 The George Institute for Global Health, New Delhi, India (V.J.).
7 Hôpital Rangueil, Toulouse, France (N.K.).
8 Hennepin Healthcare Research Institute, Minneapolis, Minnesota (B.L.K.).
9 The University of Hong Kong, Pokfulam, Hong Kong (C.L.).
10 Hospital 12 de Octubre, Madrid, Spain (J.M.M.).
11 Centers for Disease Control and Prevention, Atlanta, Georgia (P.R.P.).
12 Hôpital Cochin, and Université Paris Descartes, Paris, France (S.P.).
13 Hospital Universitario Austral and Latin American Liver Research, Educational and Awareness Network, Buenos Aires, Argentina (M.O.S.).
14 Brown University School of Public Health, Providence, Rhode Island (E.M.B.).
15 Kidney Disease: Improving Global Outcomes, Brussels, Belgium (A.E., M.C.).
16 Rhode Island Hospital and Brown University, Providence, Rhode Island (M.D.).
17 Université Catholique de Louvain, Brussels, Belgium (M.J.).
18 University of Miami, Miami, Florida (P.M.).
The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs) in the management of HCV infection in the CKD population.
The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the English-language literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification.
The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.